POLYMORPHISM IN THE HUMAN-COMPLEMENT C4 GENES AND GENETIC SUSCEPTIBILITY TO AUTOIMMUNE HEPATITIS

被引:44
作者
DOHERTY, DG
UNDERHILL, JA
DONALDSON, PT
MANABE, K
MIELIVERGANI, G
EDDLESTON, ALWF
VERGANI, D
DEMAINE, AG
WILLIAMS, R
机构
[1] From the Institute of Liver studies, King's College School of Medicine and Dentistry, London, SE5 9RS, Denmark Hill
[2] Department of Child Health, King's College School of Medicine and Dentistry, London, SE5 9RS, Denmark Hill
[3] Immunology, King's College School of Medicine and Dentistry, London, SE5 9RS, Denmark Hill
[4] Medicine, King's College School of Medicine and Dentistry, London, SE5 9RS, Denmark Hill
关键词
AUTOIMMUNE HEPATITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; COMPLEMENT; DNA POLYMORPHISM;
D O I
10.3109/08916939409009525
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Susceptibility to autoimmune hepatitis is associated with the HLA-DR3 and DR4 haplotypes, but which genes are directly involved in the pathogenesis, has not been established. Low levels of complement component C4 and elevated frequencies of C4 null allotypes have been described in patients, suggesting that the C4 genes, which are closely linked with the HLA loci, may play a role. We therefore examined restriction fragment length polymorphisms in the C4 and 21-hydroxylase genes, and determined HLA-A and B phenotypes, and HLA-DR, DQ and DP genotypes in a large series of Caucasoid patients with autoimmune hepatitis and matched controls. A DNA deletion of the C4A gene and the 21-hydroxylase A pseudogene was found to be present in 50% of patients compared to 23% of controls (P-c < 0.005, relative risk = 3.3). This increase, however, appears to be due to linkage disequilibrium with HLA-DR52a which was most strongly associated with the disease. Complete C4A deficiency, determined by homozygosity for the deletion increased the risk to 18.1 (16% versus 1%, P-c < 0.005), suggesting an additional role for C4 in disease susceptibility. C4 deletions were associated with an increased mortality and tendency to relapse whilst on treatment but did not correlate with age of onset of disease. Our data suggest that MHC-encoded susceptibility to autoimmune hepatitis is polygenic, involving the HLA-DR genes plus other loci, and C4 deficiency may be a marker of disease susceptibility and/or severity.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 45 条
[1]  
Johnson P.J., McFarlane I.G., Eddleston A.L.W.F., The natural course and heterogeneity of autoimmune-type chronic active hepatitis, Semin Liver Dis, 11, pp. 187-196, (1991)
[2]  
Eggink H.F., Houthoff H.J., Huitema S., Gips C.H., Poppema S., Cellular and humoral immune reactions in chronic active liver disease: I. Lymphocyte subsets in liver biopsies of patients with untreated idiopathic autoimmune hepatitis chronic active hepatitis B and primary biliary cirrhosis, Clin Exp Immunol, 50, pp. 17-24, (1982)
[3]  
Wen L., Peakman M., Lobo-Yeo A., McFarlane B.M., Mowat A.P., Mieli-Vcrgani G., Vergani D., T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis, Lancet, 336, pp. 1527-1530, (1990)
[4]  
Lohr H., Treichel U., Poralla T., Manns M., Meyerzum Buschenfelde K.-H., Fleischer B., The human hepatic asialo-glycoprotein receptor is a target antigen for liver-infiltrating T cells in autoimmune chronic active hepatitis and primary biliary cirrhosis, Hepatology, 12, pp. 1314-1320, (1990)
[5]  
Treichel U., Poralla T., Hess G., Manns M., Meyerzum Buschenfelde K.-H., Autoantibodies to human asialoglyco-protein receptor in autoimmune-type chronic hepatitis, Hepatology, 11, pp. 606-610, (1990)
[6]  
Mackay I.R., Tait B.D., HLA association with autoimmune-type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies, Gastroenterology, 79, pp. 95-98, (1980)
[7]  
Donaldson P.T., Doherty D.G., Hayller K.M., McFarlane I.G., Johnson P.J., Williams R., Susceptibility to autoimmune chronic active hepatitis: human leucocyte antigens DR4 and A1-B8-DR3 are independent risk factors, Hepatology, 13, pp. 701-706, (1991)
[8]  
Trowsdale J., Campbell R.D., Camplexity in the major histocompatibility complex, Eur J lmmunogenet, 19, pp. 45-55, (1992)
[9]  
Finlayson N.D.C., Krohn K., Fauconnet M.H., Anderson K.E., Significance of serum complement levels in chronic liver disease, Gastroenterology, 63, pp. 653-659, (1972)
[10]  
Munoz L.E., De Villicrs D., Markham D., Whaley K., Thomas H.C., Complement activation in chronic liver disease, Clin Exp Immunol, 47, pp. 548-554, (1982)